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Background
Event-free survival (EFS) endpoints are composite end-
points frequently used in cancer gene expression studies
to evaluate the effects of gene expression on patient out-
comes. Event free Survival endpoints in oncology, such as
Overall survival, typically combine both cancer-specific
‘death from cancer’ and non-cancer specific events ‘death
from other causes’. Reporting analysis on each event com-
prising the composite endpoint is necessary to draw more
specific inferences regarding outcomes, especially in the
presence of competing risks. The extent to which cancer-
specific and non-specific events are separated in contem-
porary gene expression studies in oncology is unknown.
Methods
We identified 259 gene expression studies published
between June 2007 and January 2012, with analysis of at
least one EFS endpoint. We excluded meta-analyses
(n=14), studies in recurrent/metastatic disease (n=22,) stu-
dies without EFS endpoints and studies that censored
competing events (n=39), studies in foreign languages
(n=4), retracted, irrelevant to research topic or unavailable
online (n=22). The remaining 158 studies were indepen-
dently evaluated by two reviewers according to the extent
of reporting on each of the events comprising the EFS
endpoint.
Results
Sixteen studies could not be categorized because end-
points such as EFS were undefined or ambiguously
defined. Of the remaining 142 studies, fifteen (10.6%;
95% confidence interval (CI), 5.4-16.2%) reported effects
on both cancer and non-cancer events comprising the
EFS endpoint. None of these reported any statistical
analysis. Forty-Two studies (29.6%; 95% CI, 21.1-35.9%)
reported only the effect on the cancer-specific compo-
nent of endpoints, but not its complement, with statisti-
cal analysis provided in 18 (12.7%; 95% CI, 6.8-19.3%).
In eighty-five studies (59%; 95% CI, 50.4-69.3%), no
effects on cancer-specific components of the EFS end-
points were given.
Conclusions
The majority of gene expression studies do not report
cancer-specific effects comprising the Event Free Survival
endpoints. Increased specificity is required in the design
and reporting of cancer gene expression studies.
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